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The 5HT3 antagonists are a new class of anti-emetic which
act by blocking 5HT3 receptors both centrally and in the
gastrointestinal tract (Costall et al., 1986; Miner et al., 1986).
Ondansetron (GR38032F, Glaxo Ltd) is a 5HT3 antagonist
which has been shown to be effective in preventing the emesis
associated with cancer chemotherapy (Cunningham et al.,
1987; Kriss et al., 1988). However, there remain patients
whose symptoms are inadequately controlled by Ondansetron
or conventional agents used alone and this study examines
the effect of a combination of Ondansetron plus dex-
amethasone in such a group. The patients entered in the
study continued to receive the same chemotherapy which had
failed previous anti-emetic prophylaxis (Table I). All patients
had failed (>5 emetic episodes) both a combination of dex-
amethasone (8 mg tds) plus metoclopramide (20 mg 4 hourly)
and single agent Ondansetron (8 mg tds). The study protocol
consisted of Ondansetron 8 mg tds for 5 days plus dex-
amethasone 8 mg tds for 48 h. The first dose of each drug
was administered 15 min before commencing the
chemotherapy. Nausea, vomiting, anorexia and any addi-
tional unpleasant symptoms were recorded on diary cards for
the 5 days following therapy. Response was graded in the
following manner: complete response (CR), no emetic
episodes; major response (MR), 1-2 emetic episodes; minor
response (mR), 3-5 emetic episodes; fail (F), more than five
emetic episodes. An emetic episode was defined as either a
vomit (any episode productive of liquid) or as 1-5 retches
within a 5 min period where a retch is a 'vomit' not produc-
tive of liquid. Statistical analysis was by comparison of pro-
portions using paired data (Armitage & Berry, 1987).
Fourteen patients were entered in the study between June
and October 1988 and their characteristics are shown in
Table II. Ten received cisplatin based chemotherapy at a
Table I Chemotherapy schedules
Results
No of
Patients CR MR mR F
Etoposide + cisplatin 7 5 1 0 1
Etoposide + ifosfamide + cisplatin I I
Etoposide + vincristine + cisplatin I I
Cisplatin I I
Etoposide + methotrexate
+ actinomycin-D 2 2
Adriamycin + cyclophosphamide 1 I
Adriamycin + bleomycin I
+ vincrintine + DTIC I
CR, complete response; MR, 1-2 emetic episodes; mR, 3-5 emetic
episodes; F, >5 emetic episodes.
Table II Patient characteristics
Total 14
Age, median (range) 28 (18-41)
Tumour type:
Choriocarcinoma 8
Teratoma 3
Lymphoma 2
Medulloblastoma I
Refractory to Ondansetron 14
Refractory to dexamethasone 14
dose of 75 mg m-2. Nine patients (64%) had a complete
response with no nausea or vomiting. A further one patient
had a major response and three a minor response. One
patient failed. Using each patient as their own control the
CR + MR rate of 71% for the combination was highly
significant (P = 0.001). In addition to control of nausea and
vomiting it was striking that the patients achieving a com-
plete response felt entirely well with no loss of appetite
during their chemotherapy. The only side-effect noted was
mild headache in two patients. No steroid related toxicity
was seen.
Early clinical trials have confirmed the effectiveness of
5HT3 antagonists in controlling the emesis associated with
cytotoxic chemotherapy (Cunningham et al., 1987; Kriss et
al., 1988; Smith et al., 1990). However, there remain some
patients who are inadequately controlled by these agents used
alone despite the maintenance of pharmacological serum
levels of drug (Smith et al., 1990). It is likely that in such
patients several different mechanisms are responsible for
inducing vomiting and therefore in order to achieve optimum
symptomatic control combinations of anti-emetics with
separate modes of action are required. For this study dex-
amethasone was chosen for use in conjunction with
Ondansetron because it is known to be an effective anti-
emetic (Kris et al., 1985) and although the precise mechanism
of action of dexamethasone is unknown there is no evidence
that it interacts with dopaminergic or 5HT3 receptors. In
addition, when used for short periods it is largely free from
side-effects.
This study shows that 90% of patients failing both dex-
amethasone and single agent Ondansetron responded to the
combination of the two drugs suggesting major synergism
between these agents. Cunningham et al. (1989) have also
made this observation.
Ondansetron plus dexamethasone is an easily administered,
non-toxic regimen which is effective in controlling emesis in
patients refractory to conventional therapy. A randomised
trial is now in progress to confirm whether this combination
is active in patients treated with cisplatin at doses of
100-12Omgm0-2
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